This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
MOUNTAIN VIEW, Calif., June 7, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that a review article has been published
TheJournal of Diabetes and Its Complications examining the importance of weight management in the treatment of type 2 diabetes
. The article reviews treatment options, including lifestyle interventions, pharmacotherapy and surgery, citing Qsymia
® (phentermine and topiramate extended-release) capsules CIV as a treatment option.
Robert R. Henry, Robert Chilton, W. Timothy Garvey
"New options for the treatment of obesity and type 2 diabetes mellitus"
According to the article, studies have shown that moderate weight loss in obese patients with type 2 diabetes mellitus (T2DM) can lead to reductions in cardiometabolic risk factors such as dyslipidemia and hypertension and can have a substantial impact on mortality.
® (phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m
2 or greater (obese) or 27 kg/m
2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.
Important Safety Information
Qsymia (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.